Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference
Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company focused on oncology, has announced its upcoming participation at the TD Cowen 45th Annual Health Care Conference. David Hung, M.D., who serves as the company's Founder, President, and Chief Executive Officer, will deliver a presentation on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, MA.
The presentation will be accessible through a live webcast on the company's investor relations website. For those unable to attend live, an archived recording will remain available for 90 days following the event on the Nuvation Bio investor website.
Nuvation Bio (NYSE: NUVB), una compagnia biofarmaceutica globale focalizzata sull'oncologia, ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. David Hung, M.D., fondatore, presidente e amministratore delegato della compagnia, presenterà il suo intervento lunedì 3 marzo 2025, alle 15:10 ET a Boston, MA.
La presentazione sarà accessibile tramite una diretta streaming sul sito web delle relazioni con gli investitori dell'azienda. Per coloro che non possono partecipare dal vivo, una registrazione archiviata sarà disponibile per 90 giorni dopo l'evento sul sito web degli investitori di Nuvation Bio.
Nuvation Bio (NYSE: NUVB), una empresa biofarmacéutica global centrada en oncología, ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen. David Hung, M.D., quien es el fundador, presidente y director ejecutivo de la empresa, realizará una presentación el lunes 3 de marzo de 2025, a las 3:10 p.m. ET en Boston, MA.
La presentación estará disponible a través de una transmisión en vivo en el sitio web de relaciones con inversores de la empresa. Para aquellos que no puedan asistir en vivo, una grabación archivada estará disponible durante 90 días después del evento en el sitio web de inversores de Nuvation Bio.
누베이션 바이오 (NYSE: NUVB), 온콜로지에 중점을 둔 글로벌 생명공학 회사가 TD 코웬 제45회 연례 헬스케어 컨퍼런스에 참여할 예정이라고 발표했습니다. 데이비드 헝, M.D.는 회사의 창립자이자 회장, CEO로서 2025년 3월 3일 월요일 오후 3시 10분 ET에 보스턴, MA에서 발표를 할 것입니다.
발표는 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트로 제공됩니다. 생중계에 참석할 수 없는 분들을 위해, 행사 후 90일 동안 누베이션 바이오 투자자 웹사이트에서 아카이브된 녹화본이 제공됩니다.
Nuvation Bio (NYSE: NUVB), une entreprise biopharmaceutique mondiale axée sur l'oncologie, a annoncé sa prochaine participation à la 45ème Conférence Annuelle sur la Santé de TD Cowen. David Hung, M.D., qui est le fondateur, président et directeur général de l'entreprise, fera une présentation le lundi 3 mars 2025, à 15h10 ET à Boston, MA.
La présentation sera accessible via un webinaire en direct sur le site web des relations avec les investisseurs de l'entreprise. Pour ceux qui ne peuvent pas assister en direct, un enregistrement archivé sera disponible pendant 90 jours après l'événement sur le site des investisseurs de Nuvation Bio.
Nuvation Bio (NYSE: NUVB), ein globales biopharmazeutisches Unternehmen mit Schwerpunkt auf Onkologie, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. David Hung, M.D., der als Gründer, Präsident und CEO des Unternehmens fungiert, wird am Montag, den 3. März 2025, um 15:10 Uhr ET in Boston, MA, eine Präsentation halten.
Die Präsentation wird über einen Live-Stream auf der Investor-Relations-Website des Unternehmens zugänglich sein. Für diejenigen, die nicht live teilnehmen können, wird eine archivierte Aufzeichnung 90 Tage nach der Veranstaltung auf der Investor-Website von Nuvation Bio verfügbar sein.
- None.
- None.
A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following the event.
About Nuvation Bio
Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio’s programs include taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224501820/en/
Nuvation Bio Investor:
ir@nuvationbio.com
Nuvation Bio Media:
media@nuvationbio.com
Source: Nuvation Bio Inc.
FAQ
When is Nuvation Bio (NUVB) presenting at the TD Cowen Healthcare Conference 2025?
How long will Nuvation Bio's (NUVB) TD Cowen conference presentation recording be available?
Where can I watch Nuvation Bio's (NUVB) TD Cowen conference presentation?
Who will represent Nuvation Bio (NUVB) at the 2025 TD Cowen Healthcare Conference?
